Invesco
CERE

Invesco’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Invesco’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-57,337
Closed -$2.34M – 3934
2024
Q2 		$2.34M Buy
57,337
+17,993
+46% +$749K ﹤0.01% 2524
2024
Q1 		$1.66M Buy
39,344
+8,830
+29% +$371K ﹤0.01% 2749
2023
Q4 		$1.29M Sell
30,514
-1,494
-5% -$42.9K ﹤0.01% 2784
2023
Q3 		$699K Sell
32,008
-366
-1% -$9.16K ﹤0.01% 3037
2023
Q2 		$1.03M Buy
32,374
+458
+1% +$14.1K ﹤0.01% 2879
2023
Q1 		$778K Buy
31,916
+1,263
+4% +$37.1K ﹤0.01% 3024
2022
Q4 		$967K Buy
30,653
+7,875
+35% +$222K ﹤0.01% 2952
2022
Q3 		$643K Buy
22,778
+1,654
+8% +$49.3K ﹤0.01% 3119
2022
Q2 		$558K Buy
21,124
+3,724
+21% +$106K ﹤0.01% 3279
2022
Q1 		$610K Sell
17,400
-344
-2% -$10K ﹤0.01% 3297
2021
Q4 		$575K Sell
17,744
-337,144
-95% -$11.9M ﹤0.01% 3329
2021
Q3 		$10.5M Buy
354,888
+342,534
+2,773% +$9.62M ﹤0.01% 1979
2021
Q2 		$317K Buy
+12,354
New +$177K ﹤0.01% 3606

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Invesco's CERE Position: Q3 2024 in Review

Invesco sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 57,337 shares — an estimated $2.34M sold.

Invesco first reported a position in CERE in Q2 2021 and held it in 13 quarters. The position peaked at $10.5M in Q3 2021. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Invesco reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Invesco sold 57,337 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $2.34M.
  • Invesco first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 13 quarters.
  • Invesco's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $10.5M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Invesco's 13F filing for Q3 2024, filed 12 Nov 2024.